Deloitte’s 2023 cell and gene therapy industry survey aimed to address the scarcity of CGT-specific information regarding past and future challenges across the value chain. The survey highlighted the key challenges and opportunities that organizations, their partners, and the broader cell and gene therapy market face. When examining the sentiments expressed by stakeholders, CGT innovators and health care providers had a positive sentiment about the industry over the past 12–18 months. Approximately 86% of CGT innovators and 83% of health care providers felt that this period had been positive for CGTs. In contrast, only 66% of CDMOs shared the same sentiment. However, in looking ahead to the next 12–18 months, there is a more positive outlook across all stakeholder groups.
Read the full article: 2023 Cell and Gene Therapy Industry Survey //
Source: https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/cell-gene-therapy-market-insights-survey.html